首页 > 最新文献

Journal of the Saudi Heart Association最新文献

英文 中文
Mitral Valve Prolapse with Syncope: Don't Judge the Book by its Cover! 二尖瓣脱垂伴晕厥:不要以貌取人!
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-13 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1395
Ghadah A Alarify, Lama A Alrumaih, Sameer Qetab, Wael Alqarawi

A 33-year-old female with recurrent syncope episodes showed normal ECG and Holter results, but had mitral valve prolapse (MVP) with moderate mitral regurgitation (MR) on an echocardiogram. Cardiovascular magnetic resonance (CMR) revealed mitral annulus disjunction (MAD) with fibrosis. She received an implantable loop recorder (ILR). Several months later, she experienced a syncope event, which correlated with self-terminating polymorphic ventricular tachycardia (PMVT) preceded by narrow complex tachycardia, which was proven to be atrioventricular nodal reentrant tachycardia (AVNRT) in an electrophysiology study. Post-ablation, she had no recurrences of syncope. This case highlights the importance of ILR in avoiding unnecessary ICDs in MVP patients with syncope.

一名 33 岁女性反复晕厥发作,心电图和 Holter 结果显示正常,但超声心动图显示二尖瓣脱垂(MVP)伴中度二尖瓣反流(MR)。心血管磁共振(CMR)显示二尖瓣瓣环脱节(MAD)并伴有纤维化。她接受了植入式环路记录器(ILR)。几个月后,她经历了一次晕厥,晕厥与自终末多形性室性心动过速(PMVT)有关,之前是窄复律心动过速,电生理学研究证实这是房室结性返流性心动过速(AVNRT)。消融术后,她没有再出现晕厥。该病例强调了 ILR 在避免晕厥 MVP 患者不必要使用 ICD 方面的重要性。
{"title":"Mitral Valve Prolapse with Syncope: Don't Judge the Book by its Cover!","authors":"Ghadah A Alarify, Lama A Alrumaih, Sameer Qetab, Wael Alqarawi","doi":"10.37616/2212-5043.1395","DOIUrl":"10.37616/2212-5043.1395","url":null,"abstract":"<p><p>A 33-year-old female with recurrent syncope episodes showed normal ECG and Holter results, but had mitral valve prolapse (MVP) with moderate mitral regurgitation (MR) on an echocardiogram. Cardiovascular magnetic resonance (CMR) revealed mitral annulus disjunction (MAD) with fibrosis. She received an implantable loop recorder (ILR). Several months later, she experienced a syncope event, which correlated with self-terminating polymorphic ventricular tachycardia (PMVT) preceded by narrow complex tachycardia, which was proven to be atrioventricular nodal reentrant tachycardia (AVNRT) in an electrophysiology study. Post-ablation, she had no recurrences of syncope. This case highlights the importance of ILR in avoiding unnecessary ICDs in MVP patients with syncope.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 3","pages":"301-304"},"PeriodicalIF":0.7,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Sternotomy Access Versus Thoracotomy Access in the Surgical Treatment of Aortic Coarctation: A Propensity Score-matched Study. 在主动脉粥样硬化的手术治疗中,鞘膜切开术入路与胸廓切开术入路的比较:倾向评分匹配研究
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-13 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1396
Ilya A Soynov, Ksenya A Rzayeva, Yuriy N Gorbatykh, Yuriy Y Kulyabin, Artem V Gorbatykh, Ilya A Velyukhanov, Nataliya R Nichay, Serezha N Manukian, Saihuna A Magbulova, Aleksey N Arkhipov, Aleksander V Bogachev-Prokophiev

Background: The search for the "Holy Grail" of surgical repair for aortic coarctation involves finding an access and correction method that successfully and consistently avoids aortic recoarctation and arterial hypertension. The controversy persists as there is still no consensus on the best surgical approach and technique to achieve these objectives.

Objective: The objective of this study is to compare sternotomy and left thoracotomy as surgical techniques for treating patients with aortic coarctation and hypoplasia of the distal aortic arch.

Methods: From January 2008 to December 2020, 103 surgical procedures were performed using an extended oblique anastomosis. The patients were divided into 2 groups: oblique, extended anastomosis from thoracotomy access (n-68; 66%) and oblique extended anastomosis from sternotomy access (n-35; 34%). After performing a propensity score analysis (1:1) for the entire sample, 25 patients from sternotomy access were matched with 25 patients from thoracotomy access.

Results: The mortality rate in the thoracotomy group was 4%, with 1 patient, while it was 8% with 2 patients in the sternotomy group, p > 0.99. There were no significant differences in early postoperative complications between the two groups. Recurrence of aortic coarctation was observed more frequently in the thoracotomy group (20.8% vs 0%). Low weight was identified as the only risk factor for aortic re-coarctation.

Conclusion: The mortality rates and early postoperative complications associated with the surgical repair of aortic coarctation were similar between the sternotomy and thoracotomy approaches. Nevertheless, sternotomy approach may be beneficial in reducing aortic recoarctation.

背景:寻找主动脉粥样硬化手术修复的 "圣杯",包括找到一种能够成功且持续避免主动脉再梗阻和动脉高血压的入路和矫正方法。由于对实现这些目标的最佳手术方法和技术仍未达成共识,因此争议一直存在:本研究旨在比较胸骨切开术和左胸廓切开术作为治疗主动脉瓣闭锁和主动脉弓远端发育不良患者的手术技术:方法:2008年1月至2020年12月,103例手术采用了扩展斜吻合术。患者分为两组:从胸廓切开术入路进行斜行扩展吻合术(n-68;66%)和从胸骨切开术入路进行斜行扩展吻合术(n-35;34%)。在对整个样本进行倾向评分分析(1:1)后,25 名胸骨切开术入路的患者与 25 名胸廓切开术入路的患者进行了配对:结果:胸廓切开术组的死亡率为 4%,其中 1 名患者死亡,而胸骨切开术组的死亡率为 8%,其中 2 名患者死亡,P > 0.99。两组患者术后早期并发症无明显差异。胸廓切开术组的主动脉缩窄复发率更高(20.8% 对 0%)。体重过轻是主动脉再狭窄的唯一风险因素:结论:胸骨切开术和胸廓切开术手术修复主动脉缩窄的死亡率和术后早期并发症相似。尽管如此,胸骨切开术可能有利于减少主动脉再梗塞。
{"title":"Comparison of Sternotomy Access Versus Thoracotomy Access in the Surgical Treatment of Aortic Coarctation: A Propensity Score-matched Study.","authors":"Ilya A Soynov, Ksenya A Rzayeva, Yuriy N Gorbatykh, Yuriy Y Kulyabin, Artem V Gorbatykh, Ilya A Velyukhanov, Nataliya R Nichay, Serezha N Manukian, Saihuna A Magbulova, Aleksey N Arkhipov, Aleksander V Bogachev-Prokophiev","doi":"10.37616/2212-5043.1396","DOIUrl":"10.37616/2212-5043.1396","url":null,"abstract":"<p><strong>Background: </strong>The search for the \"Holy Grail\" of surgical repair for aortic coarctation involves finding an access and correction method that successfully and consistently avoids aortic recoarctation and arterial hypertension. The controversy persists as there is still no consensus on the best surgical approach and technique to achieve these objectives.</p><p><strong>Objective: </strong>The objective of this study is to compare sternotomy and left thoracotomy as surgical techniques for treating patients with aortic coarctation and hypoplasia of the distal aortic arch.</p><p><strong>Methods: </strong>From January 2008 to December 2020, 103 surgical procedures were performed using an extended oblique anastomosis. The patients were divided into 2 groups: oblique, extended anastomosis from thoracotomy access (n-68; 66%) and oblique extended anastomosis from sternotomy access (n-35; 34%). After performing a propensity score analysis (1:1) for the entire sample, 25 patients from sternotomy access were matched with 25 patients from thoracotomy access.</p><p><strong>Results: </strong>The mortality rate in the thoracotomy group was 4%, with 1 patient, while it was 8% with 2 patients in the sternotomy group, p > 0.99. There were no significant differences in early postoperative complications between the two groups. Recurrence of aortic coarctation was observed more frequently in the thoracotomy group (20.8% vs 0%). Low weight was identified as the only risk factor for aortic re-coarctation.</p><p><strong>Conclusion: </strong>The mortality rates and early postoperative complications associated with the surgical repair of aortic coarctation were similar between the sternotomy and thoracotomy approaches. Nevertheless, sternotomy approach may be beneficial in reducing aortic recoarctation.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 3","pages":"305-315"},"PeriodicalIF":0.7,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142574996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease. 沙特心脏协会关于肥胖与心血管疾病的立场声明。
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1391
Waleed Alhabeeb, Abdulhalim J Kinsara, Abeer Bakhsh, Adel Tash, Afaf Alshammary, Ali Almasood, Kamal Alghalayini, Mohammed Arafah, Osama Hamdy, Saud Alsifri, Suleiman M Kharabsheh, Wail Alkattan

Objectives: The obesity pandemic is a major public health concern in Saudi Arabia, with significant impact on cardiovascular disease (CVD). This position statement aims to provide an overview of available evidence as well as the recommendations of the Saudi Heart Association on the management of obesity associated with CVD.

Methods: Under the auspices of the Saudi Heart Association, a multidisciplinary expert panel comprised of cardiologists and endocrinologists discussed available evidence and provided recommendations on the management of obesity in CVD. The expert panel discussions occurred between September of 2023 and May of 2024 and also took into consideration local expertise in addition to published data in the management of obesity and CVD in the Kingdom of Saudi Arabia.

Results and conclusions: The expert panel explored studies on obesity and its implication on CVD assessment modalities, while also examining the efficacy and cardiovascular safety of available interventions for weight reduction. The association between obesity and CVD is undeniable. The treatment of obesity, be it through lifestyle changes, pharmacological therapy or surgery, is an effective strategy for both weight loss as well as the primary and secondary prevention of CVD. The Saudi Heart Association position statement thus provides guidance and recommendations for the management of obesity/overweight and CVD in Saudi Arabia. This position statement is expected to contribute towards obesity and CVD prevention efforts in Saudi Arabia by promoting adequate and time-appropriate treatment of these conditions.

目的:肥胖症是沙特阿拉伯的一大公共卫生问题,对心血管疾病(CVD)有重大影响。本立场声明旨在概述现有证据以及沙特心脏协会对心血管疾病相关肥胖症管理的建议:在沙特心脏协会的主持下,由心脏病专家和内分泌专家组成的多学科专家小组讨论了现有证据,并就肥胖对心血管疾病的管理提出了建议。专家小组的讨论在 2023 年 9 月至 2024 年 5 月期间进行,除了沙特阿拉伯王国肥胖和心血管疾病管理方面已发表的数据外,还考虑了当地的专业知识:专家小组探讨了有关肥胖及其对心血管疾病影响评估方式的研究,同时还审查了现有减轻体重干预措施的有效性和心血管安全性。肥胖与心血管疾病之间的联系是不可否认的。无论是通过改变生活方式、药物治疗还是手术治疗肥胖症,都是减轻体重以及心血管疾病一级和二级预防的有效策略。因此,沙特心脏协会的立场声明为沙特阿拉伯的肥胖/超重和心血管疾病管理提供了指导和建议。通过促进对肥胖和心血管疾病进行充分和适时的治疗,该立场声明有望为沙特阿拉伯的肥胖和心血管疾病预防工作做出贡献。
{"title":"A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease.","authors":"Waleed Alhabeeb, Abdulhalim J Kinsara, Abeer Bakhsh, Adel Tash, Afaf Alshammary, Ali Almasood, Kamal Alghalayini, Mohammed Arafah, Osama Hamdy, Saud Alsifri, Suleiman M Kharabsheh, Wail Alkattan","doi":"10.37616/2212-5043.1391","DOIUrl":"10.37616/2212-5043.1391","url":null,"abstract":"<p><strong>Objectives: </strong>The obesity pandemic is a major public health concern in Saudi Arabia, with significant impact on cardiovascular disease (CVD). This position statement aims to provide an overview of available evidence as well as the recommendations of the Saudi Heart Association on the management of obesity associated with CVD.</p><p><strong>Methods: </strong>Under the auspices of the Saudi Heart Association, a multidisciplinary expert panel comprised of cardiologists and endocrinologists discussed available evidence and provided recommendations on the management of obesity in CVD. The expert panel discussions occurred between September of 2023 and May of 2024 and also took into consideration local expertise in addition to published data in the management of obesity and CVD in the Kingdom of Saudi Arabia.</p><p><strong>Results and conclusions: </strong>The expert panel explored studies on obesity and its implication on CVD assessment modalities, while also examining the efficacy and cardiovascular safety of available interventions for weight reduction. The association between obesity and CVD is undeniable. The treatment of obesity, be it through lifestyle changes, pharmacological therapy or surgery, is an effective strategy for both weight loss as well as the primary and secondary prevention of CVD. The Saudi Heart Association position statement thus provides guidance and recommendations for the management of obesity/overweight and CVD in Saudi Arabia. This position statement is expected to contribute towards obesity and CVD prevention efforts in Saudi Arabia by promoting adequate and time-appropriate treatment of these conditions.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 3","pages":"263-300"},"PeriodicalIF":0.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to Cardiac Rehabilitation Enrollment and Secondary Prevention Adherence in Patients with Coronary Heart Disease Following Percutaneous Coronary Intervention: A Cross-sectional Survey. 经皮冠状动脉介入治疗后冠心病患者参加心脏康复治疗和坚持二级预防的障碍:横断面调查。
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1392
Ahmed M Almoghairi, Jane O'Brien, Anna Doubrovsky, Jed Duff

Objectives: This study aimed to evaluate adherence to secondary prevention measures and to identify barriers to cardiac rehabilitation enrolment among patients with coronary heart disease after percutaneous coronary intervention.

Methods: An observational cross-sectional survey was conducted through computer-assisted telephone interviews to assess recently treated percutaneous coronary intervention patients at the Prince Sultan Cardiac Center in Saudi Arabia.

Results: Out of 104 surveyed patients with coronary heart disease, 85 (82%) were male, with an average age of 59.5 years. The obesity rate was 28% (n = 29), with a high prevalence of comorbidities: 82 (79%), 63 (61%), and 62 (60%) patients had hyperlipidemia, diabetes, and hypertension, respectively. Despite high medication compliance (97%), adherence to secondary prevention measures was low (21%). Adherence to physical exercise and weight monitoring for fluid body build-up was notably poor at 35% and 9%, respectively. Only 11 (10.6%) patients were referred for cardiac rehabilitation, of whom only four (36.4%) attended. Significant barriers such as a lack of staff contact, insufficient physician support, and distance to cardiac rehabilitation facilities were particularly noted by 69% of rural patients.

Conclusions: This study underscores the significant cardiac risk factors and low adherence to secondary prevention measures among post revascularization patients with coronary heart disease in Saudi Arabia. Low referral and other organizational barriers, as well as the travel distance to hospital-based cardiac rehabilitation, hinder program enrolment. To improve cardiac rehabilitation accessibility, it is crucial to revise the discharge plans, implement automated referral systems, expand the services across all regions, and utilize alternative delivery models.

研究目的本研究旨在评估经皮冠状动脉介入治疗后的冠心病患者对二级预防措施的依从性,并确定心脏康复注册的障碍:通过计算机辅助电话访问,对沙特阿拉伯苏尔坦亲王心脏中心近期接受经皮冠状动脉介入治疗的患者进行了观察性横断面调查:在接受调查的 104 名冠心病患者中,85 名(82%)为男性,平均年龄为 59.5 岁。肥胖率为 28%(n = 29),合并症发病率高:82(79%)、63(61%)和 62(60%)名患者分别患有高脂血症、糖尿病和高血压。尽管服药依从性很高(97%),但二级预防措施的依从性却很低(21%)。坚持体育锻炼和监测体重以防止体内积液的比例明显较低,分别为 35% 和 9%。只有 11 名(10.6%)患者被转介到心脏康复中心,其中只有 4 名(36.4%)参加了康复治疗。69%的农村患者特别指出了一些重大障碍,如缺乏工作人员的联系、医生支持不足以及距离心脏康复机构太远等:这项研究强调了沙特阿拉伯冠心病血运重建术后患者的重要心脏风险因素和二级预防措施的低依从性。转诊率低和其他组织障碍,以及前往医院心脏康复中心的路途遥远,都阻碍了该计划的实施。要提高心脏康复的可及性,关键是要修改出院计划、实施自动转诊系统、在所有地区扩大服务范围并采用其他服务模式。
{"title":"Barriers to Cardiac Rehabilitation Enrollment and Secondary Prevention Adherence in Patients with Coronary Heart Disease Following Percutaneous Coronary Intervention: A Cross-sectional Survey.","authors":"Ahmed M Almoghairi, Jane O'Brien, Anna Doubrovsky, Jed Duff","doi":"10.37616/2212-5043.1392","DOIUrl":"10.37616/2212-5043.1392","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to evaluate adherence to secondary prevention measures and to identify barriers to cardiac rehabilitation enrolment among patients with coronary heart disease after percutaneous coronary intervention.</p><p><strong>Methods: </strong>An observational cross-sectional survey was conducted through computer-assisted telephone interviews to assess recently treated percutaneous coronary intervention patients at the Prince Sultan Cardiac Center in Saudi Arabia.</p><p><strong>Results: </strong>Out of 104 surveyed patients with coronary heart disease, 85 (82%) were male, with an average age of 59.5 years. The obesity rate was 28% (<i>n</i> = 29), with a high prevalence of comorbidities: 82 (79%), 63 (61%), and 62 (60%) patients had hyperlipidemia, diabetes, and hypertension, respectively. Despite high medication compliance (97%), adherence to secondary prevention measures was low (21%). Adherence to physical exercise and weight monitoring for fluid body build-up was notably poor at 35% and 9%, respectively. Only 11 (10.6%) patients were referred for cardiac rehabilitation, of whom only four (36.4%) attended. Significant barriers such as a lack of staff contact, insufficient physician support, and distance to cardiac rehabilitation facilities were particularly noted by 69% of rural patients.</p><p><strong>Conclusions: </strong>This study underscores the significant cardiac risk factors and low adherence to secondary prevention measures among post revascularization patients with coronary heart disease in Saudi Arabia. Low referral and other organizational barriers, as well as the travel distance to hospital-based cardiac rehabilitation, hinder program enrolment. To improve cardiac rehabilitation accessibility, it is crucial to revise the discharge plans, implement automated referral systems, expand the services across all regions, and utilize alternative delivery models.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 3","pages":"252-262"},"PeriodicalIF":0.7,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11517995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Elderly Patients With Severe Symptomatic Aortic Stenosis: A Systematic Review. 严重症状性主动脉瓣狭窄老年患者经导管主动脉瓣置换术与外科主动脉瓣置换术的疗效比较:系统回顾。
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-26 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1393
Omar Hamodat, Saif Almuzainy, Salma Nizar

Objectives: Aortic stenosis is the most common valvular heart disease globally; while transcatheter aortic valve replacement (TAVR) has proven to be a competitive alternative to surgical aortic valve replacement (SAVR) and revolutionized treatment, its safety and efficacy has yet to be comprehensively assessed against SAVR for certain subsets of aortic stenosis patients; therefore, this study aims to systematically analyze all the available clinical evidence from randomized clinical trials on TAVR versus SAVR among intermediate and low-risk patients with severe symptomatic aortic stenosis.

Methodology: We performed a systematic review of the randomized controlled trials (RCT), studies comparing TAVR and SAVR in low- and intermediate-risk patients were identified by a comprehensive search of the major databases. Mortality, stroke, length of stay, and other perioperative outcomes were assessed.

Results: A comprehensive screening of 14,384 records identified 9 studies, encompassing 8884 patients with a mean age of 77.76 years and 49.47% male. TAVR demonstrated a significantly lower all-cause mortality at both 30 days and 1 year compared to SAVR, with comparable outcomes at 2 years, underscoring its potential for enhanced survival. Stroke incidence was markedly lower with TAVR at both 30 days and 1 year, highlighting its favorable neurological safety profile. Additionally, TAVR showed a reduced rate of myocardial infarction within the initial 30 days post-procedure. Prosthetic valve endocarditis rates remained low and comparable between the two approaches at both 30 days and 1 year. Notably, TAVR was associated with a significantly shorter hospital stay, suggesting a faster recovery trajectory and improved patient throughput. These findings collectively emphasize the superior efficacy and safety profile of TAVR over SAVR.

Conclusion: TAVR may serve as a viable therapeutic option for intermediate and low-risk patients with severe symptomatic aortic stenosis. Future research should focus on long-term outcomes and TAVR device durability, especially in younger, lower-risk populations.

目的:主动脉瓣狭窄是全球最常见的瓣膜性心脏病:主动脉瓣狭窄是全球最常见的瓣膜性心脏病;虽然经导管主动脉瓣置换术(TAVR)已被证明是手术主动脉瓣置换术(SAVR)的一种有竞争力的替代方法,并为治疗带来了革命性的变化,但对于某些主动脉瓣狭窄患者亚群,其安全性和有效性仍有待与 SAVR 进行全面评估;因此,本研究旨在系统分析在中低风险重度症状性主动脉瓣狭窄患者中进行 TAVR 与 SAVR 比较的随机临床试验的所有可用临床证据。研究方法:我们对随机对照试验(RCT)进行了系统回顾,通过对主要数据库的全面检索,确定了在中低风险患者中比较 TAVR 和 SAVR 的研究。对死亡率、中风、住院时间和其他围手术期结果进行了评估:结果:通过对 14384 条记录的全面筛选,确定了 9 项研究,涉及 8884 名患者,平均年龄 77.76 岁,男性占 49.47%。与 SAVR 相比,TAVR 在 30 天和 1 年内的全因死亡率明显降低,2 年内的结果也相当,这突显了其提高生存率的潜力。TAVR术后30天和1年的中风发生率都明显降低,突出了其良好的神经系统安全性。此外,TAVR 还降低了术后最初 30 天内的心肌梗死发生率。人工瓣膜心内膜炎发生率仍然很低,两种方法在术后 30 天和 1 年内的发生率相当。值得注意的是,TAVR 的住院时间明显更短,这表明患者的恢复速度更快,患者吞吐量更高。这些发现共同强调了 TAVR 比 SAVR 更优越的疗效和安全性:结论:TAVR可作为严重症状性主动脉瓣狭窄的中低风险患者的可行治疗方案。未来的研究应重点关注长期疗效和TAVR设备的耐用性,尤其是在年轻的低风险人群中。
{"title":"Comparative Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Elderly Patients With Severe Symptomatic Aortic Stenosis: A Systematic Review.","authors":"Omar Hamodat, Saif Almuzainy, Salma Nizar","doi":"10.37616/2212-5043.1393","DOIUrl":"10.37616/2212-5043.1393","url":null,"abstract":"<p><strong>Objectives: </strong>Aortic stenosis is the most common valvular heart disease globally; while transcatheter aortic valve replacement (TAVR) has proven to be a competitive alternative to surgical aortic valve replacement (SAVR) and revolutionized treatment, its safety and efficacy has yet to be comprehensively assessed against SAVR for certain subsets of aortic stenosis patients; therefore, this study aims to systematically analyze all the available clinical evidence from randomized clinical trials on TAVR versus SAVR among intermediate and low-risk patients with severe symptomatic aortic stenosis.</p><p><strong>Methodology: </strong>We performed a systematic review of the randomized controlled trials (RCT), studies comparing TAVR and SAVR in low- and intermediate-risk patients were identified by a comprehensive search of the major databases. Mortality, stroke, length of stay, and other perioperative outcomes were assessed.</p><p><strong>Results: </strong>A comprehensive screening of 14,384 records identified 9 studies, encompassing 8884 patients with a mean age of 77.76 years and 49.47% male. TAVR demonstrated a significantly lower all-cause mortality at both 30 days and 1 year compared to SAVR, with comparable outcomes at 2 years, underscoring its potential for enhanced survival. Stroke incidence was markedly lower with TAVR at both 30 days and 1 year, highlighting its favorable neurological safety profile. Additionally, TAVR showed a reduced rate of myocardial infarction within the initial 30 days post-procedure. Prosthetic valve endocarditis rates remained low and comparable between the two approaches at both 30 days and 1 year. Notably, TAVR was associated with a significantly shorter hospital stay, suggesting a faster recovery trajectory and improved patient throughput. These findings collectively emphasize the superior efficacy and safety profile of TAVR over SAVR.</p><p><strong>Conclusion: </strong>TAVR may serve as a viable therapeutic option for intermediate and low-risk patients with severe symptomatic aortic stenosis. Future research should focus on long-term outcomes and TAVR device durability, especially in younger, lower-risk populations.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 3","pages":"242-251"},"PeriodicalIF":0.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11517992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Rare Case of Large Nonvalvular Papillary Fibroelastoma Manifesting as Vertigo and Exertional Dyspnea. 表现为眩晕和劳力性呼吸困难的巨大非瓣状乳头状纤维母细胞瘤的罕见病例
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-25 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1394
Mohaddeseh Behjati, Mohsen Mirmohammadsadeghi, Ehsan Abadi, Mohammad H Paknahad, Parisa Adib-Hajbagheri

Background: Papillary fibroelastoma (PFE) is an uncommon benign cardiac tumor, typically arising from valvular structures. Nonvalvular PFEs are exceedingly rare and may present with diverse symptoms.

Case presentation: We present a case of a 46-year-old woman with positional vertigo and exertional dyspnea. Transthoracic echocardiography revealed a mobile oval-shaped mass in the left ventricle. Cardiac magnetic resonance imaging suggested a large papillary fibroelastoma. The tumor was successfully resected, and histopathological examination confirmed the diagnosis.

Conclusion: This case highlights the importance of thorough imaging and surgical intervention in managing large, nonvalvular PFEs, which, although rare, can lead to significant complications.

背景:乳头状纤维母细胞瘤(PFE)是一种不常见的心脏良性肿瘤,通常发生于瓣膜结构。非瓣膜性乳头状纤维瘤极为罕见,可能表现出多种症状:我们介绍了一例 46 岁女性的病例,她患有位置性眩晕和劳力性呼吸困难。经胸超声心动图显示左心室有一个移动的椭圆形肿块。心脏磁共振成像提示为巨大乳头状纤维瘤。肿瘤被成功切除,组织病理学检查确诊:本病例强调了彻底成像和手术干预在处理大的非瓣膜性 PFEs 中的重要性,尽管这种 PFEs 很罕见,但可导致严重的并发症。
{"title":"A Rare Case of Large Nonvalvular Papillary Fibroelastoma Manifesting as Vertigo and Exertional Dyspnea.","authors":"Mohaddeseh Behjati, Mohsen Mirmohammadsadeghi, Ehsan Abadi, Mohammad H Paknahad, Parisa Adib-Hajbagheri","doi":"10.37616/2212-5043.1394","DOIUrl":"https://doi.org/10.37616/2212-5043.1394","url":null,"abstract":"<p><strong>Background: </strong>Papillary fibroelastoma (PFE) is an uncommon benign cardiac tumor, typically arising from valvular structures. Nonvalvular PFEs are exceedingly rare and may present with diverse symptoms.</p><p><strong>Case presentation: </strong>We present a case of a 46-year-old woman with positional vertigo and exertional dyspnea. Transthoracic echocardiography revealed a mobile oval-shaped mass in the left ventricle. Cardiac magnetic resonance imaging suggested a large papillary fibroelastoma. The tumor was successfully resected, and histopathological examination confirmed the diagnosis.</p><p><strong>Conclusion: </strong>This case highlights the importance of thorough imaging and surgical intervention in managing large, nonvalvular PFEs, which, although rare, can lead to significant complications.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 3","pages":"237-241"},"PeriodicalIF":0.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consensus of the National Heart Center in collaboration With the Saudi Arabian Cardiac Interventional Society on the Clinical Use of Intracoronary Imaging. 国家心脏中心与沙特阿拉伯心脏介入学会就冠状动脉内成像的临床应用达成共识。
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-01 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1387
Mirvat Alasnag, Mognee Alameer, Ahmed AlShehri, Hind Alosaimi, Faisal Alqoofi, Hussain Alzayer, Wail AlKashkari, Adel Tash, Waqar H Ahmed

Objectives: Studies show that intracoronary imaging (ICI)-guided PCI is associated with a significantly lower risk of stroke, Q-wave myocardial infarction, and death compared to angiography-guided PCI in the management of acute coronary syndromes, complex coronary lesions and left-main interventions. Despite these well-established clinical benefits, the utilization of ICI-guided PCI in Saudi Arabia remains suboptimal.

Methods: The National Heart Center (NHC) and the Saudi Arabian Cardiac Interventional Society (SACIS) gathered national experts to develop a consensus document on how to integrate ICI-guided PCI in routine clinical practice in Saudi Arabia. The consensus was based on the nominal group technique, whereby a committee of interventional cardiologists affiliated with the NHS and SACIS developed and discussed a number of statements on the clinical use of intracoronary imaging based on a systematic review of the literature.

Results: A total of 17 statements were discussed in light of scientific evidence and agreed upon. Initiatives to improve operator skills when it comes to image acquisition and interpretation are crucial in the incorporation of ICI-imaging guided PCI in Saudi Arabia. Local data on reference diameters and measurements and epidemiological data on Saudi patients being treated in catheterization laboratories are necessary.

Conclusions: Herein, we provide the first national consensus on the use of ICI-guided PCI in Saudi Arabia. We anticipate that this document contributes to a more optimal and integrative use of ICI-guided PCI in the Kingdom.

目的:研究表明,在急性冠状动脉综合征、复杂冠状动脉病变和左主干介入治疗中,冠状动脉内成像(ICI)引导的 PCI 与血管造影引导的 PCI 相比,中风、Q 波心肌梗死和死亡的风险明显降低。尽管有这些公认的临床益处,但在沙特阿拉伯,在 ICI 引导下进行 PCI 治疗的利用率仍未达到最佳水平:方法:国家心脏中心(NHC)和沙特阿拉伯心脏介入学会(SACIS)召集了国内专家,就如何将 ICI 引导下的 PCI 纳入沙特阿拉伯的常规临床实践制定了一份共识文件。该共识以名义小组技术为基础,由隶属于 NHS 和 SACIS 的介入心脏病专家组成的委员会在系统回顾文献的基础上,就冠状动脉内成像的临床应用制定并讨论了一系列声明:结果:根据科学证据共讨论了 17 项声明,并达成一致意见。在沙特阿拉伯,提高操作者的图像采集和解读技能对于采用 ICI 成像引导的 PCI 至关重要。关于参考直径和测量值的本地数据以及在导管室接受治疗的沙特患者的流行病学数据都是必要的:在此,我们首次就在沙特阿拉伯使用 ICI 引导的 PCI 达成了全国共识。我们希望这份文件能为沙特阿拉伯王国更优化、更全面地使用 ICI 引导的 PCI 做出贡献。
{"title":"Consensus of the National Heart Center in collaboration With the Saudi Arabian Cardiac Interventional Society on the Clinical Use of Intracoronary Imaging.","authors":"Mirvat Alasnag, Mognee Alameer, Ahmed AlShehri, Hind Alosaimi, Faisal Alqoofi, Hussain Alzayer, Wail AlKashkari, Adel Tash, Waqar H Ahmed","doi":"10.37616/2212-5043.1387","DOIUrl":"10.37616/2212-5043.1387","url":null,"abstract":"<p><strong>Objectives: </strong>Studies show that intracoronary imaging (ICI)-guided PCI is associated with a significantly lower risk of stroke, Q-wave myocardial infarction, and death compared to angiography-guided PCI in the management of acute coronary syndromes, complex coronary lesions and left-main interventions. Despite these well-established clinical benefits, the utilization of ICI-guided PCI in Saudi Arabia remains suboptimal.</p><p><strong>Methods: </strong>The National Heart Center (NHC) and the Saudi Arabian Cardiac Interventional Society (SACIS) gathered national experts to develop a consensus document on how to integrate ICI-guided PCI in routine clinical practice in Saudi Arabia. The consensus was based on the nominal group technique, whereby a committee of interventional cardiologists affiliated with the NHS and SACIS developed and discussed a number of statements on the clinical use of intracoronary imaging based on a systematic review of the literature.</p><p><strong>Results: </strong>A total of 17 statements were discussed in light of scientific evidence and agreed upon. Initiatives to improve operator skills when it comes to image acquisition and interpretation are crucial in the incorporation of ICI-imaging guided PCI in Saudi Arabia. Local data on reference diameters and measurements and epidemiological data on Saudi patients being treated in catheterization laboratories are necessary.</p><p><strong>Conclusions: </strong>Herein, we provide the first national consensus on the use of ICI-guided PCI in Saudi Arabia. We anticipate that this document contributes to a more optimal and integrative use of ICI-guided PCI in the Kingdom.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 2","pages":"137-157"},"PeriodicalIF":0.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoperative Remifentanil Use Reduces Atrial Fibrillation After Coronary Artery Bypass Surgery. 术中使用瑞芬太尼可减少冠状动脉搭桥手术后的心房颤动
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-17 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1390
Yasuhiko Imashuku, Susumu Hiraoka, Motoi Inoue, Takayoshi Mizuno, Misuzu Oyagi, Hirotoshi Kitagawa

Objectives: Atrial fibrillation after coronary artery bypass grafting is a relatively well known complication that has been observed for a long time. Though the management and drugs in the perioperative period have changed, their impact on the generation of postoperative atrial fibrillation remains unclear. Therefore, we investigated various perioperative management methods and the occurrence of postoperative atrial fibrillation.

Methods: The patients underwent off-pump coronary artery bypass grafting between January 2010 and October 2019. The study was a retrospective observational study, and we investigated the incidence of atrial fibrillation during all 5 postoperative days. Patient factors included age, sex, height, and weight, preoperative factors included oral statin, HbA1c, left ventricular ejection fraction, and left atrial diameter; intraoperative factors included operation time, remifentanil use, beta-blocker use, magnesium-containing infusions use, in-out balance, and number of vascular anastomoses.

Results: Postoperative atrial fibrillation was recognized in 81 out of 276 cases. There were significant differences between the two groups in terms of age, left atrial diameter, and intraoperative remifentanil use. A logistic regression analysis presented the effects of age (OR 1.045, 95% CI 1.015-1.076, P < 0.01), preoperative left atrial diameter (OR 1.072, 95% CI 1.023-1.124, P < 0.01), and intraoperative remifentanil use (OR 0.492, 95% CI 0.284-0.852, P = 0.011) on postoperative atrial fibrillation.

Conclusions: Operative time did not affect postoperative atrial fibrillation. Age and left atrial diameter had previously been shown to affect postoperative atrial fibrillation, and our results were similar. This study showed that the use of remifentanil reduced the incidence of postoperative atrial fibrillation. On the other hand, no other factors were found to have an effect.

目的:冠状动脉旁路移植术后的心房颤动是一种相对众所周知的并发症,已经观察了很长时间。虽然围手术期的管理和药物发生了变化,但它们对术后心房颤动发生的影响仍不明确。因此,我们研究了各种围手术期管理方法和术后心房颤动的发生率:患者于 2010 年 1 月至 2019 年 10 月间接受了体外循环冠状动脉搭桥术。该研究是一项回顾性观察研究,我们调查了术后5天内心房颤动的发生率。患者因素包括年龄、性别、身高和体重,术前因素包括口服他汀类药物、HbA1c、左心室射血分数和左心房直径;术中因素包括手术时间、瑞芬太尼使用情况、β-受体阻滞剂使用情况、含镁输液使用情况、出入量平衡和血管吻合次数:结果:276个病例中有81个发现术后心房颤动。两组患者在年龄、左心房直径和术中使用瑞芬太尼方面存在明显差异。逻辑回归分析显示了年龄(OR 1.045,95% CI 1.015-1.076,P <0.01)、术前左房直径(OR 1.072,95% CI 1.023-1.124,P <0.01)和术中使用瑞芬太尼(OR 0.492,95% CI 0.284-0.852,P = 0.011)对术后房颤的影响:手术时间对术后心房颤动没有影响。结论:手术时间对术后心房颤动没有影响。年龄和左心房直径曾被证明会影响术后心房颤动,我们的结果与之相似。本研究表明,使用瑞芬太尼可降低术后心房颤动的发生率。另一方面,没有发现其他因素有影响。
{"title":"Intraoperative Remifentanil Use Reduces Atrial Fibrillation After Coronary Artery Bypass Surgery.","authors":"Yasuhiko Imashuku, Susumu Hiraoka, Motoi Inoue, Takayoshi Mizuno, Misuzu Oyagi, Hirotoshi Kitagawa","doi":"10.37616/2212-5043.1390","DOIUrl":"10.37616/2212-5043.1390","url":null,"abstract":"<p><strong>Objectives: </strong>Atrial fibrillation after coronary artery bypass grafting is a relatively well known complication that has been observed for a long time. Though the management and drugs in the perioperative period have changed, their impact on the generation of postoperative atrial fibrillation remains unclear. Therefore, we investigated various perioperative management methods and the occurrence of postoperative atrial fibrillation.</p><p><strong>Methods: </strong>The patients underwent off-pump coronary artery bypass grafting between January 2010 and October 2019. The study was a retrospective observational study, and we investigated the incidence of atrial fibrillation during all 5 postoperative days. Patient factors included age, sex, height, and weight, preoperative factors included oral statin, HbA1c, left ventricular ejection fraction, and left atrial diameter; intraoperative factors included operation time, remifentanil use, beta-blocker use, magnesium-containing infusions use, in-out balance, and number of vascular anastomoses.</p><p><strong>Results: </strong>Postoperative atrial fibrillation was recognized in 81 out of 276 cases. There were significant differences between the two groups in terms of age, left atrial diameter, and intraoperative remifentanil use. A logistic regression analysis presented the effects of age (OR 1.045, 95% CI 1.015-1.076, P < 0.01), preoperative left atrial diameter (OR 1.072, 95% CI 1.023-1.124, P < 0.01), and intraoperative remifentanil use (OR 0.492, 95% CI 0.284-0.852, P = 0.011) on postoperative atrial fibrillation.</p><p><strong>Conclusions: </strong>Operative time did not affect postoperative atrial fibrillation. Age and left atrial diameter had previously been shown to affect postoperative atrial fibrillation, and our results were similar. This study showed that the use of remifentanil reduced the incidence of postoperative atrial fibrillation. On the other hand, no other factors were found to have an effect.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 3","pages":"232-236"},"PeriodicalIF":0.7,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Saudi Heart Association/National Heart Center/Saudi Arabian Cardiac Interventional Society/Saudi Society for Cardiac Surgeons/Saudi Cardiac Imaging Group 2023 TAVI Guidelines. 沙特心脏协会/国家心脏中心/沙特阿拉伯心脏介入学会/沙特心脏外科医师学会/沙特心脏成像小组 2023 年 TAVI 指南。
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-15 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1379
Turki Albacker, Adel Tash, Hussein Alamri, Mirvat Alasnag, Wail Alkashkari, Fawaz Almutairi, Faisal Alqoofi, Ahmed Alsaileek, Uthman Aluthman, Ghormallah Alzahrani, Mohammed Balghith, Fahd Makhdom

Saudi Arabia has seen a significant improvement in its healthcare system over the past four decades resulting in an increase in life-expectancy. Transcatheter aortic valve implantation (TAVI) has spread widely in Saudi Arabia and has become a routine procedure in many centers. The expanding clinical indications and the availability of the technology have made it possible for many large and intermediate centers all over the country to commence their own TAVI programs. So, the aim of this document is to standardize TAVI practices in different Saudi Arabian centers through reasonable guidelines based on the evaluation and summarization of the best available evidence. The review committee, composed of different experts in several aspects of the management of patient undergoing TAVI, based their recommendations on the reviewed and analyzed evidence and the class and level of recommendations were discussed until a consensus was reached by the panel.

在过去的四十年里,沙特阿拉伯的医疗保健系统得到了显著改善,延长了患者的预期寿命。经导管主动脉瓣植入术(TAVI)已在沙特阿拉伯广泛开展,并已成为许多中心的常规手术。随着临床适应症的不断扩大和技术的普及,全国许多大型和中型中心都开始了自己的 TAVI 项目。因此,本文件的目的是在评估和总结现有最佳证据的基础上,通过合理的指南来规范沙特阿拉伯不同中心的 TAVI 操作。评审委员会由接受 TAVI 患者管理多个方面的不同专家组成,他们根据审查和分析的证据提出建议,并对建议的类别和级别进行讨论,直至小组达成共识。
{"title":"Saudi Heart Association/National Heart Center/Saudi Arabian Cardiac Interventional Society/Saudi Society for Cardiac Surgeons/Saudi Cardiac Imaging Group 2023 TAVI Guidelines.","authors":"Turki Albacker, Adel Tash, Hussein Alamri, Mirvat Alasnag, Wail Alkashkari, Fawaz Almutairi, Faisal Alqoofi, Ahmed Alsaileek, Uthman Aluthman, Ghormallah Alzahrani, Mohammed Balghith, Fahd Makhdom","doi":"10.37616/2212-5043.1379","DOIUrl":"10.37616/2212-5043.1379","url":null,"abstract":"<p><p>Saudi Arabia has seen a significant improvement in its healthcare system over the past four decades resulting in an increase in life-expectancy. Transcatheter aortic valve implantation (TAVI) has spread widely in Saudi Arabia and has become a routine procedure in many centers. The expanding clinical indications and the availability of the technology have made it possible for many large and intermediate centers all over the country to commence their own TAVI programs. So, the aim of this document is to standardize TAVI practices in different Saudi Arabian centers through reasonable guidelines based on the evaluation and summarization of the best available evidence. The review committee, composed of different experts in several aspects of the management of patient undergoing TAVI, based their recommendations on the reviewed and analyzed evidence and the class and level of recommendations were discussed until a consensus was reached by the panel.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 2","pages":"184-231"},"PeriodicalIF":0.7,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Two is Company, Three is a Crowd" - A Case Presentation of Cardiac Amyloidosis, Hypertrophic Cardiomyopathy Plus Coronary Heart Disease. "二人为伴,三人成群"--心脏淀粉样变性、肥厚性心肌病加冠心病的病例介绍。
IF 0.7 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-12 eCollection Date: 2024-01-01 DOI: 10.37616/2212-5043.1389
Carolina M Gonçalves, Mariana Carvalho, Célia Domingues, Fátima Saraiva, João Morais

A 76-year-old man was referred to our appointment with complaints of exertional dyspnea. He had a medical history consisting of chronic coronary syndrome, hypertrophic cardiomyopathy, and an implantable cardioverter-defibrillator for primary prevention. A transthoracic echocardiogram revealed features suspicious for cardiac amyloidosis. Haematologic and genetic tests were negative, and scintigraphy was positive, confirming wild-type transthyretin amyloidosis, not eligible for tafamidis. Several months later with optimized medical therapy, he had two worsening heart failure events. This clinical case highlights the importance of differential diagnosis. Our patient had both hypertrophic cardiomyopathy and transthyretin amyloidosis, a rare association that constitutes a diagnostic and treatment challenge.

一名 76 岁的男性因主诉劳累性呼吸困难而被转诊至我院。他的病史包括慢性冠状动脉综合征、肥厚型心肌病和用于一级预防的植入式心律转复除颤器。经胸超声心动图显示,他有心脏淀粉样变性的可疑特征。血液学和基因检测均为阴性,闪烁扫描呈阳性,证实为野生型转甲状腺素淀粉样变性,不符合他法米迪治疗条件。几个月后,经过优化的药物治疗,他出现了两次心力衰竭恶化。这个临床病例强调了鉴别诊断的重要性。我们的患者同时患有肥厚型心肌病和经淀粉样蛋白淀粉样变性,这种罕见的合并症给诊断和治疗带来了挑战。
{"title":"\"Two is Company, Three is a Crowd\" - A Case Presentation of Cardiac Amyloidosis, Hypertrophic Cardiomyopathy Plus Coronary Heart Disease.","authors":"Carolina M Gonçalves, Mariana Carvalho, Célia Domingues, Fátima Saraiva, João Morais","doi":"10.37616/2212-5043.1389","DOIUrl":"10.37616/2212-5043.1389","url":null,"abstract":"<p><p>A 76-year-old man was referred to our appointment with complaints of exertional dyspnea. He had a medical history consisting of chronic coronary syndrome, hypertrophic cardiomyopathy, and an implantable cardioverter-defibrillator for primary prevention. A transthoracic echocardiogram revealed features suspicious for cardiac amyloidosis. Haematologic and genetic tests were negative, and scintigraphy was positive, confirming wild-type transthyretin amyloidosis, not eligible for tafamidis. Several months later with optimized medical therapy, he had two worsening heart failure events. This clinical case highlights the importance of differential diagnosis. Our patient had both hypertrophic cardiomyopathy and transthyretin amyloidosis, a rare association that constitutes a diagnostic and treatment challenge.</p>","PeriodicalId":17319,"journal":{"name":"Journal of the Saudi Heart Association","volume":"36 2","pages":"178-183"},"PeriodicalIF":0.7,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the Saudi Heart Association
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1